title: HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers.
abstract: This paper investigates the presence of HLA class I-restricted and tumor-specific cytotoxic T lymphocytes (CTL) in tumor sites of esophageal cancers. Five CTL lines were established from the metastatic lymph nodes or pleural effusion by incubation with interleukin-2 of tumor-infiltrating lymphocytes: cases 1 and 5, HLA-A26- and HLA-A33-restricted and squamous cell carcinoma (SCC)-specific CTL; case 2, HLA-Cw0102-restricted and esophageal SCC-specific CTL; case 3, HLA-A24- and HLA-A26-restricted CTL recognizing histologically different tumor cells; and case 4, HLA-A26-restricted and esophageal SCC-specific CTL. These results suggest the existence of HLA class I-restricted and tumor-specific CTL in metastatic esophageal SCC.
authors.affiliation: First Department of Surgery, Kurume University School of Medicine, Asahi-machi, Japan.
authors.forename: U
authors.initials: U
authors.lastname: Toh
authors.forename: H
authors.initials: H
authors.lastname: Yamana
authors.forename: M
authors.initials: M
authors.lastname: Nakao
authors.forename: Y
authors.initials: Y
authors.lastname: Imai
authors.forename: N
authors.initials: N
authors.lastname: Seki
authors.forename: H
authors.initials: H
authors.lastname: Takasu
authors.forename: T
authors.initials: T
authors.lastname: Kaneshige
authors.forename: H
authors.initials: H
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Shirouzu
authors.forename: K
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000368:Aged; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology / Q000556:secondary*; D003601:Cytotoxicity Tests, Immunologic; D018076:DNA, Complementary / Q000235:genetics; D004938:Esophageal Neoplasms / Q000276:immunology / Q000473:pathology*; D015234:HLA-A Antigens / Q000235:genetics / Q000276:immunology*; D059871:HLA-A24 Antigen; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D008207:Lymphatic Metastasis / Q000276:immunology* / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000473:pathology; D009928:Organ Specificity; D016066:Pleural Effusion, Malignant / Q000276:immunology / Q000473:pathology*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D018076:DNA, Complementary; D015234:HLA-A Antigens; C039683:HLA-A*26 antigen; C082945:HLA-A*33 antigen; D059871:HLA-A24 Antigen; D007376:Interleukin-2